Arginine deprivation therapy for malignant melanoma
Jung-Ki Yoon,1,2 Arthur E Frankel,3 Lynn G Feun,4 Suhendan Ekmekcioglu,1 Kevin B Kim11Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Hwasung Public Health Center, Hwasung, South Korea, 3Scott and White Cancer Research Insti...
Main Authors: | Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-12-01
|
Series: | Clinical Pharmacology: Advances and Applications |
Online Access: | http://www.dovepress.com/arginine-deprivation-therapy-for-malignant-melanoma-a11816 |
Similar Items
-
The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
by: Niramol Savaraj, et al.
Published: (2007-01-01) -
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
by: Chunjing Wu, et al.
Published: (2021-07-01) -
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
by: Carpentier J, et al.
Published: (2022-09-01) -
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
by: Lukas Kraehenbuehl, et al.
Published: (2022-05-01) -
Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
by: Naihui Sun, et al.
Published: (2022-07-01)